Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Toray, JT, Torii Terminate Joint Development of Additional Indication for Nalfurafine
Toray Industries, Japan Tobacco (JT), and Torii Pharmaceutical announced on December 22 that they had agreed to terminate their joint development of nalfurafine HCl (Toray development code: TRK-820) developed by Toray for an additional indication to treat pruritus associated with…
To read the full story
BUSINESS
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…